French pharma company Servier has entered into a research partnership with UK biotech MiNA Therapeutics to develop small activating RNA (saRNA) therapies for the treatment of neurological diseases.
Roche and Jnana Therapeutics have entered into a collaboration to discover new medicines targeting key regulators of cellular metabolism to treat immune-mediated and neurological diseases.
Biogen and Sangamo Therapeutics have signed a global licensing agreement for the development of drugs to treat neurological diseases, including Alzheimer’s and Parkinson’s diseases.